Genscript Biotech Corporation
Genscript Biotech Corporation Fundamental Analysis
Genscript Biotech Corporation (GNNSF) shows moderate financial fundamentals with a PE ratio of 0.66, profit margin of 5.64%, and ROE of 71.23%. The company generates $1.0B in annual revenue with weak year-over-year growth of -29.19%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 23.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze GNNSF's fundamental strength across five key dimensions:
Efficiency Score
ExcellentGNNSF demonstrates superior asset utilization.
Valuation Score
ExcellentGNNSF trades at attractive valuation levels.
Growth Score
ModerateGNNSF shows steady but slowing expansion.
Financial Health Score
ExcellentGNNSF maintains a strong and stable balance sheet.
Profitability Score
ModerateGNNSF maintains healthy but balanced margins.
Key Financial Metrics
Is GNNSF Expensive or Cheap?
P/E Ratio
GNNSF trades at 0.66 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, GNNSF's PEG of 0.13 indicates potential undervaluation.
Price to Book
The market values Genscript Biotech Corporation at 0.47 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 9.00 times EBITDA. This is generally considered low.
How Well Does GNNSF Make Money?
Net Profit Margin
For every $100 in sales, Genscript Biotech Corporation keeps $5.64 as profit after all expenses.
Operating Margin
Core operations generate 63.89 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $71.23 in profit for every $100 of shareholder equity.
ROA
Genscript Biotech Corporation generates $57.25 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Genscript Biotech Corporation generates strong operating cash flow of $423.34M, reflecting robust business health.
Free Cash Flow
Genscript Biotech Corporation generates strong free cash flow of $338.05M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.15 in free cash annually.
FCF Yield
GNNSF converts 4.77% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
0.66
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.13
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.47
vs 25 benchmark
P/S Ratio
Price to sales ratio
6.93
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.12
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.96
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.71
vs 25 benchmark
ROA
Return on assets percentage
0.57
vs 25 benchmark
ROCE
Return on capital employed
0.07
vs 25 benchmark
How GNNSF Stacks Against Its Sector Peers
| Metric | GNNSF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 0.66 | 29.45 | Better (Cheaper) |
| ROE | 71.23% | 779.00% | Weak |
| Net Margin | 563.80% | -24936.00% (disorted) | Strong |
| Debt/Equity | 0.12 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 1.96 | 4.65 | Neutral |
| ROA | 57.25% | -19344.00% (disorted) | Strong |
GNNSF outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Genscript Biotech Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
85.00%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
2699.89%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
314.83%
Industry Style: Defensive, Growth, Innovation
High Growth